7.79
+0.28(+3.73%)
Currency In USD
| Previous Close | 7.51 |
| Open | 7.5 |
| Day High | 7.96 |
| Day Low | 7.31 |
| 52-Week High | 9.76 |
| 52-Week Low | 4.2 |
| Volume | 452,479 |
| Average Volume | 465,280 |
| Market Cap | 425.95M |
| PE | -3.42 |
| EPS | -2.28 |
| Moving Average 50 Days | 7.55 |
| Moving Average 200 Days | 7.84 |
| Change | 0.28 |
If you invested $1000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, it would be worth $38.95 as of May 09, 2025 at a share price of $7.79. Whereas If you bought $1000 worth of Zevra Therapeutics, Inc. (ZVRA) shares 5 years ago, it would be worth $1,872.6 as of May 09, 2025 at a share price of $7.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
GlobeNewswire Inc.
May 06, 2025 11:30 AM GMT
Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025CELEBRATION, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapi
Zevra Therapeutics to Participate in the Citizens Life Science Conference
GlobeNewswire Inc.
May 01, 2025 8:05 PM GMT
CELEBRATION, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that members of Zevra’s executive leadership team will part
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
GlobeNewswire Inc.
Apr 17, 2025 11:30 AM GMT
CELEBRATION, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication